NCT05972278View on ClinicalTrials.gov

Investigating the Effect of Obicetrapib on Lipoprotein Metabolism

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

December 1, 2023

Primary Completion Date

September 26, 2024

Study Completion Date

October 14, 2024

Conditions
Lipid Metabolism
Interventions
DRUG

Obicetrapib

1 tablet daily

Trial Locations (1)

19104

Archna Bajaj, MD, Philadelphia

Sponsors
All Listed Sponsors
collaborator

University of Pennsylvania

OTHER

lead

NewAmsterdam Pharma

INDUSTRY